Neothetics, Inc
13
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
1 terminated/withdrawn out of 13 trials
91.7%
+5.2% vs industry average
23%
3 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202
Role: collaborator
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
Role: collaborator
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
Role: lead
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat
Role: lead
Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects
Role: lead
An Open-Label Study to Evaluate Retreatment With LIPO-202
Role: lead
An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity
Role: lead
Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)
Role: lead
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
Role: lead
Dose Ranging Study
Role: lead
Dose-ranging Study
Role: lead
An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers
Role: lead
Dose Ranging and Dose Frequency of LIPO-102
Role: lead
All 13 trials loaded